Chemotherapy followed by ablative SBRT for locally advanced inoperable pancreatic cancer
Official title: Efficacy Of Combination Chemotherapy And Ablative Radiotherapy (SBRT) In The First-Line Treatment Of Locally Advanced Inoperable Pancreatic Cancer
Run by Institute of Oncology Ljubljana · NCT07407231 · Data updated 2026-11-12
This trial will try chemotherapy followed by high-dose focused radiation (SBRT) as the first treatment for adults with locally advanced, inoperable pancreatic cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Institute of Oncology Ljubljana Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Ljubljana) |
| Status | Recruiting |
| Started | September 1, 2021 |
| Main results expected | September 30, 2024 |
| Study ends | December 31, 2026 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07407231 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with locally advanced, inoperable pancreatic cancer who have not received prior systemic therapy for this stage and who do not progress on initial first-line chemotherapy are ideal candidates.
✕Probably not a fit
Patients with metastatic disease, those who progress during initial chemotherapy, or those unfit for SBRT or systemic therapy are unlikely to benefit from this combined approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, non-randomized study enrolling adults with locally advanced, inoperable pancreatic cancer who receive standard first-line systemic chemotherapy. Patients without disease progression after initial chemotherapy undergo ablative stereotactic body radiotherapy (SBRT) directed to the primary pancreatic tumor, with systemic therapy continued afterward as clinically indicated. The primary outcome is tumor response rate after SBRT, with secondary endpoints including time to disease progression and treatment-related toxicity. The study is run at the Institute of Oncology Ljubljana in Slovenia with expansion to additional participating centers after amendment.
Why it matters
Potential benefit: If successful, this approach could improve local tumor control, delay progression, and reduce symptoms related to the primary pancreatic tumor.
How similar studies have gone: Non-randomized series and early-phase studies of SBRT in locally advanced pancreatic cancer have shown improved local control and acceptable toxicity, but clear survival benefit remains uncertain.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years and older * Locally advanced, inoperable pancreatic cancer * Treated with first-line systemic chemotherapy followed by stereotactic body radiotherapy (SBRT) at participating centers * Ability to provide written informed consent Exclusion Criteria: * Metastatic pancreatic cancer * Prior systemic therapy for locally advanced pancreatic cancer (one or more previous lines of systemic treatment) * Disease progression after initial chemotherapy prior to SBRT * Any condition that, in the investigator's opinion, would interfere with study participation or evaluation
Where it's running
-
Institute of Oncology Ljubljana
Ljubljana, Slovenia Recruiting
Study contacts
- Study coordinator: Janja Ocvirk, MD
- Email: jocvirk@onko-i.si
- Phone: 01 5879 220
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chemotherapy With IMD10 (Focused Ultrasound) for Borderline Resectable or Locally Advanced Pancreatic Cancer
This trial tests whether adding IMD10 focused ultrasound to a standard chemotherapy regimen helps people with borderline resectable or locally advanced pancreatic cancer see better survival.
-
Personalized management for borderline resectable and locally advanced pancreatic cancer
This study is testing if giving chemotherapy first can help people with borderline resectable and locally advanced pancreatic cancer have surgery and improve their chances of survival.
-
Combination treatment for advanced pancreatic cancer
This study is testing a new combination treatment for advanced pancreatic cancer to see if it helps patients who haven't had treatment before.
-
Alpha DaRT for Locally Advanced Pancreatic Cancer test
This trial tests inserting Alpha DaRT sources into a locally advanced pancreatic tumor to see if it can become resectable.
-
Comparing two treatments for locally advanced pancreatic cancer
This study is testing two different treatment combinations for people with locally advanced pancreatic cancer to see which one works better.
-
Assessing the effects of radiotherapy on tumors in cervical and pancreatic cancer
This study is testing how radiotherapy affects tumors in patients with locally advanced cervical and pancreatic cancer by collecting samples and using special imaging before, during, and after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.